In today’s recent session, 1.75 million shares of the 10x Genomics Inc (NASDAQ:TXG) have been traded, and its beta is 1.89. Most recently the company’s share price was $12.40, and it changed around -$1.85 or -12.98% from the last close, which brings the market valuation of the company to $1.50B. TXG at last check was trading at a discount to its 52-week high of $51.22, offering almost -313.06% off that amount. The share price’s 52-week low was $12.95, which indicates that the recent value has fallen by an impressive -4.44% since then. We note from 10x Genomics Inc’s average daily trading volume that its 10-day average is 2.05 million shares, with the 3-month average coming to 1.96 million.
10x Genomics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.37. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 8 recommended TXG as a Hold, whereas 6 deemed it a Buy, and 1 rated it as Underweight. 10x Genomics Inc is expected to report earnings per share of -0.11 for the current quarter.
10x Genomics Inc (NASDAQ:TXG) trade information
Instantly TXG has been showing red trend so far today with a performance of -12.98% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 15.20 on recent trading dayincreased the stock’s daily price by 18.42%. The company’s shares are currently down -13.65% year-to-date, but still down -14.19% over the last five days. On the other hand, 10x Genomics Inc (NASDAQ:TXG) is -21.67% down in the 30-day period. We can see from the shorts that 7.61 million shares have been sold at a short interest cover period of 4.26 day(s).
The consensus price target as assigned by Wall Street analysts is $46, which translates to bulls needing to increase their stock price by 73.04% from its current value. Analyst projections state that TXG is forecast to be at a low of $46 and a high of $46.
10x Genomics Inc (TXG) estimates and forecasts
The year-over-year growth rate is expected to be -1.29%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 164.98M in revenue for the current quarter. 13 analysts expect 10x Genomics Inc to make 140.55M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 183.98M and 141.01M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -10.33%. Forecasts for the next quarter put sales growth at -0.32%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -13.04%. 10x Genomics Inc earnings are expected to increase by 35.22% in 2025, but the outlook is positive 23.61% per year for the next five years.
TXG Dividends
10x Genomics Inc’s next quarterly earnings report is expected to be released in March.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.19% of 10x Genomics Inc shares, and 99.21% of them are in the hands of institutional investors. The stock currently has a share float of 101.43%. 10x Genomics Inc stock is held by 374.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 10.8971% of the shares, which is about 13.01 million shares worth $253.05 million.
VANGUARD GROUP INC, with 8.5341% or 10.19 million shares worth $198.18 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 8.25 shares worth $100.87 million, making up 7.71% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 3.25 shares worth around $39.7 million, which represents about 3.04% of the total shares outstanding.
